LIVZON PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement.

We accept no liability for any loss caused by reliance on such content.

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

This is to set forth the "Livzon Pharmaceutical Group Co., Ltd." published on the website of the Shenzhen Stock Exchange Co., Ltd.'s Announcement on the Election of Employee Representative Directors" is for reference only.

By order of the board of directors

Livzon Pharmaceutical Group Co., Ltd. LivzonPharmaceuticalGroupInc.* company secretary Liu Ning

China, Zhuhai May 29, 2026

As at the date of this announcement, the executive directors of the Company are Mr. Liu Daping (President) and Mr. Tang Yanggang (Vice Chairman) and;

The non-executive directors are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee directors of the company are Ms. Ran Yongmei and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

*Identification only

Securities code: 000513, 01513 Securities abbreviation: Livzon Group, Livzon Pharmaceutical Announcement number: 2026-45

Livzon Pharmaceutical Group Co., Ltd.

Announcement on the Election of Employee Representative Directors

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and there are no false records.

information, misleading statements or material omissions.

Livzon Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") held on May 28, 2026

The first employee representative conference in 2026, after voting at the meeting, elected Ms. Ran Yongmei (see the attachment for resume details) as

Employee representative director of the 12th Board of Directors of the company.

After the election of employee representative directors is completed, Ms. Ran Yongmei will meet with the company’s twelfth board of directors.

The employee representative directors jointly constitute the company's twelfth board of directors and serve until the expiration of the company's twelfth board of directors.

End of day. Ms. Ran Yongmei complies with the Company Law of the People's Republic of China (hereinafter referred to as the "Company Law") and the "Company Law".

"Articles of Association" and other relevant qualifications for directors. The twelfth board of directors of the company concurrently serves as the company's senior management The total number of employees and directors held by employee representatives does not exceed one-half of the total number of directors of the company, which meets the

requirements of relevant laws and regulations.

Announcement is hereby made.

Board of Directors of Livzon Pharmaceutical Group Co., Ltd.

May 30, 2026

Attachment: Resume of Employee Representative Director

Ms. Ran Yongmei, born in 1983, is currently the employee representative director of the company. Graduated from Chongqing Medical University in 2006 University of Science and Technology and obtained a bachelor's degree in pharmacy. Ms. Ran Yongmei once worked at Shenzhen Sanofi Pasteur Biological Products Co., Ltd.

Company, Shenzhen Xinlitai Pharmaceutical Co., Ltd., and Joincare Group Shenzhen Haibin Pharmaceutical Co., Ltd. 2022

He joined the company in January 2016 and is currently the assistant to the president of the company and concurrently serves as the deputy general manager of Livzon Monoclonal Antibody.

As of the disclosure date of this announcement, Ms. Ran Yongmei does not hold any shares in the company. Ms. Ran Yongmei and the holding company

There is no related relationship between shareholders, actual controllers and other directors and senior managers of more than 5% of the shares; Received penalties from the China Securities Regulatory Commission and other relevant departments and disciplinary sanctions from stock exchanges, and has not been suspected of committing a crime

Be investigated by judicial authorities or be investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations; have not been investigated by the China Securities Regulatory Commission

Will be published on the public inquiry platform for illegal and untrustworthy information in the securities and futures markets or be included in the list of untrustworthy persons by the people's court.

List of executors; "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Main Board" does not exist

There are no situations in which nomination as a director is prohibited as stipulated in the Standardized Operation of Municipal Companies; there are no circumstances under the Company Law, Shenzhen Securities Those who are not allowed to serve as directors are prohibited from serving as directors as stipulated in the Exchange Stock Listing Rules, Articles of Association, etc.;

Act, Articles of Association, etc.